Product/Composition:- | Tenofovir DF + Emtricitabine + Elvitegravir + Cobicistat |
---|---|
Strength:- | Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TDF – 300 mg |
Form:- | Oral tablet (film-coated) |
Reference Brands:- | Stribild (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Stribild is a once-daily HIV-1 treatment combining TDF, Emtricitabine, Elvitegravir, and Cobicistat in one tablet. FDA and EMA approved, it provides effective viral suppression and improved adherence. Must be taken with food.
Tenofovir Disoproxil Fumarate (TDF) + Emtricitabine + Elvitegravir + Cobicistat, marketed as Stribild, is a complete, once-daily, single-tablet regimen for the treatment of HIV-1 infection in treatment-naïve adults and adolescents. This fixed-dose combination includes an integrase inhibitor (Elvitegravir), two NRTIs (TDF and Emtricitabine), and a pharmacokinetic booster (Cobicistat). Approved by the US FDA and EMA, Stribild offers strong viral suppression and improved patient adherence by reducing pill burden. It must be taken with food to ensure optimal absorption. Stribild is widely used in global HIV programs, though newer TAF-based regimens like Genvoya offer improved renal and bone safety.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications